Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

McCormack, Sheena; Dunn, David T; Desai, Monica; Dolling, David I; Gafos, Mitzy; Gilson, Richard; Sullivan, Ann K; Clarke, Amanda; Reeves, Iain; Schembri, Gabriel; Mackie, Nicola; Bowman, Christine; Lacey, Charles J; Apea, Vanessa; Brady, Michael; Fox, Julie; Taylor, Stephen; Antonucci, Simone; Khoo, Saye H; Rooney, James; Nardone, Anthony; Fisher, Martin; McOwan, Alan; Phillips, Andrew N; Johnson, Anne M; Gazzard, Brian; Gill, Owen N

doi:10.1016/s0140-6736(15)00056-2

Cited by 1,878HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV, Drug Use, Sexual Risk

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Open access

McCormack, Sheena, Dunn, David T, Desai, Monica, Dolling, David I, Gafos, Mitzy, Gilson, Richard, Sullivan, Ann K, Clarke, Amanda +19 more·2016·The Lancet

DOI 10.1016/s0140-6736(15)00056-2PMC PMC4700047

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection. However, this benefit could be counteracted by risk compensation in users of PrEP. We did the PROUD study to assess this effect. METHODS: PROUD is an open-label randomised trial done at 13 sexual health clinics in England. We enrolled HIV-negative gay and other men who have sex with men who had had anal intercourse without a condom in the previous 90 days. Participants were randomly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) either immediately or after a deferral period of 1 year. Randomisation was done via web-based access to a central computer-generated list with variable block sizes (stratified by clinical site). Follow-up was quarterly. The primary outcomes for the pilot phase were time to accrue 500 participants and retention; secondary outcomes included incident HIV infection during the deferral period, safety, adherence, and risk compensation. The trial is registered with ISRCTN (number ISRCTN94465371) and ClinicalTrials.gov (NCT02065986). FINDINGS: We enrolled 544 participants (275 in the immediate group, 269 in the deferred group) between Nov 29, 2012, and April 30, 2014. Based on early evidence of effectiveness, the trial steering committee recommended on Oct 13, 2014, that all deferred participants be offered PrEP. Follow-up for HIV incidence was complete for 243 (94%) of 259 patient-years in the immediate group versus 222 (90%) of 245 patient-years in the deferred group. Three HIV infections occurred in the immediate group (1·2/100 person-years) versus 20 in the deferred group (9·0/100 person-years) despite 174 prescriptions of post-exposure prophylaxis in the deferred group (relative reduction 86%, 90% CI 64-96, p=0·0001; absolute difference 7·8/100 person-years, 90% CI 4·3-11·3). 13 men (90% CI 9-23) in a similar population would need access to 1 year of PrEP to avert one HIV infection. We recorded no serious adverse drug reactions; 28 adverse events, most commonly nausea, headache, and arthralgia, resulted in interruption of PrEp. We detected no difference in the occurrence of sexually transmitted infections, including rectal gonorrhoea and chlamydia, between groups, despite a suggestion of risk compensation among some PrEP recipients. INTERPRETATION: In this high incidence population, daily tenofovir-emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting. There was no evidence of an increase in other sexually transmitted infections. Our findings strongly support the addition of PrEP to the standard of prevention for men who have sex with men at risk of HIV infection. FUNDING: MRC Clinical Trials Unit at UCL, Public Health England, and Gilead Sciences.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)00056-2

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical practice guidelines recommend STI screening for persons taking PrEP because increased rates of STI acquisition have been described.
“Clinical practice guidelines recommend STI screening for persons taking PrEP (80) because increased rates of STI acquisition have been described (85–87).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [86]
The citation to this paper is attached to the claim that STI acquisition increased, not to the guideline recommendation. The Results (page not available in our copy) report no significant difference in STIs between the immediate-PrEP and deferred groups after adjusting for the greater number of STI screens in the immediate group; the Discussion likewise says there was no measurable increase. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096 · see citing works
Self-citation
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,895 · see citing works
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256 · see citing works
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996 · see citing works
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,605 · see citing works
Sifting the evidence---what's wrong with significance tests? Another comment on the role of statistical methods
Sterne, J. A. C. (2001) · BMJ · doi:10.1136/bmj.322.7280.226 · Cited by 1,466 · see citing works
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463 · see citing works
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296 · see citing works
Self-citation
Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men
Anderson, P. L., Glidden, D. V., Liu, A., Buchbinder, S., Lama, J. R., Guanira, J. V., McMahan, V., Bushman, L. R., Casapía, M., Montoya, O., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004006 · Cited by 1,021 · see citing works
Risk compensation: the Achilles' heel of innovations in HIV prevention?
Cassell, M. M., Halperin, D. T., Shelton, J. D., & Stanton, D. (2006) · BMJ · doi:10.1136/bmj.332.7541.605 · Cited by 390 · see citing works
Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic
Phillips, A. N., Cambiano, V., Nakagawa, F., Brown, A. E., Lampe, F. C., Rodger, A. J., Miners, A. H., Elford, J., Hart, G. J., Johnson, A. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055312 · Cited by 215 · see citing works
Self-citation
B ritish HIV A ssociation guidelines for the routine investigation and monitoring of adult HIV ‐1‐infected individuals 2011
Asboe, D., Aitken, C., Boffito, M., Booth, C. L., Cane, P., Fakoya, A. O., Geretti, A. M., Kelleher, P., Mackie, N., Muir, D., et al. (2011) · HIV Medicine · doi:10.1111/j.1468-1293.2011.00971.x · Cited by 197 · see citing works
Self-citation
HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial
Buchbinder, S., Glidden, D. V., Liu, A., McMahan, V., Guanira, J. V., Mayer, K. H., Goicochea, P., & Grant, R. M. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70025-8 · Cited by 145 · see citing works
UK Standards for Microbiology Investigations
Test, N. (2014) · Cited by 131 · see citing works
HIV Treatment as Prevention: Natural Experiments Highlight Limits of Antiretroviral Treatment as HIV Prevention
Wilson, D. P. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001231 · Cited by 126 · see citing works
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa
van de Vijver, D. A. M. C., Nichols, B. E., Abbas, U. L., Boucher, C. A., Cambiano, V., Eaton, J. W., Glaubius, R. L., Lythgoe, K., Mellors, J. W., Phillips, A. N., et al. (2013) · AIDS · doi:10.1097/01.aids.0000433237.63560.20 · Cited by 71 · see citing works
Self-citation
Projected Lifetime Healthcare Costs Associated with HIV Infection
Nakagawa, F., Miners, A. H., Smith, C. J., Simmons, R., Lodwick, R. K., Cambiano, V., Lundgren, J. D., Delpech, V., & Phillips, A. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125018 · Cited by 58 · see citing works
Self-citation
The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK
McCormack, S., Fidler, S. J., & Fisher, M. (2012) · International Journal of STD & AIDS · doi:10.1258/ijsa.2011.051211 · Cited by 32 · see citing works
Self-citation
O1 Is pre-exposure prophylaxis for hiv prevention cost-effective in men who have sex with men who engage in condomless sex in the uk?
Cambiano, V., Miners, A. H., Dunn, D. T., McCormack, S., Gill, N., Nardone, A., Desai, M., Cairns, G., Rodger, A. J., & Phillips, A. N. (2015) · Sexually Transmitted Infections · doi:10.1136/sextrans-2015-052126.1 · Cited by 25 · see citing works
Self-citation
WHO ‘Treatment as Prevention’ guidelines are unlikely to decrease HIV transmission in the UK unless undiagnosed HIV infections are reduced
Brown, A. E., Nardone, A., & Delpech, V. (2013) · AIDS · doi:10.1097/qad.0000000000000137 · Cited by 23 · see citing works
Self-citation
Preexposure Chemoprophylaxis for HIV Prevention
Pittrof, R., Sauer, U., & French, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1101504 · Cited by 11 · see citing works
Interpreting and investigating proteinuria
Browne, O. T., & Bhandari, S. (2012) · BMJ · doi:10.1136/bmj.e2339 · Cited by 10 · see citing works
O4 Hiv incidence among people who attend sexual health clinics in england in 2012: estimates using a biomarker for recent infection
Aghaizu, A., Murphy, G., Tosswill, J. H. C., DeAngelis, D., Charlett, A., Gill, N., Moses, S. E., Ward, H., Hughes, G., & Delpech, V. (2015) · Sexually Transmitted Infections · doi:10.1136/sextrans-2015-052126.4 · Cited by 6 · see citing works
Evaluating HIV treatment as prevention in the European context.
Smith, C. J., Cambiano, V., O’Connor, J. L., Nakagawa, F., Lodwick, R. K., Rodger, A. J., Lampe, F. C., & Phillips, A. N. (2012) · doi:10.2900/59229 · Cited by 4 · see citing works
Self-citation

Flagged first, then by citations

Research works printed but not linked: 2

[26]Antonucci S, Desai M, Dolling D, et al. The UK PROUD PrEP Pilot study: a baseline analysis. 20th International AIDS Conference; July 20–25, 2014; Melbourne, Australia. Abstract THPE197.
[29]Molina J-M, Capitant C, Charreau I, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on Retroviruses and Opportunistic Infections; Feb 23–26, 2015; Seattle, WA, USA. Abstract 23LB.

Sorted by citations

Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 2,759 · see citing works
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Molina, J., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., Tremblay, C. L., Gall, J.-M. L., Cua, É., Pasquet, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506273 · Cited by 1,633 · see citing works
Self-citation
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506110 · Cited by 772 · see citing works
Sexually transmitted infections: challenges ahead
Unemo, M., Bradshaw, C. S., Hocking, J. S., de Vries, H. J. C., Francis, S. C., Mabey, D. C. W., Marrazzo, J. M., Sonder, G. J. B., Schwebke, J. R., Hoornenborg, E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30310-9 · Cited by 752 · see citing works
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698 · see citing works
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Günthard, H., Saag, M., Benson, C., Rio, C. D., Eron, J., Gallant, J., Hoy, J., Mugavero, M., Sax, P., Thompson, M., et al. (2016) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2016.8900 · Cited by 847 · see citing works
Gonorrhoea
Unemo, M., Seifert, H. S., Hook, E. W., Hawkes, S., Ndowa, F. J., & Dillon, J. R. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0128-6 · Cited by 536 · see citing works
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.
Bavinton, B. R., Pinto, A. N., Phanuphak, N., Grinsztejn, B., Prestage, G. P., Zablotska-Manos, I. B., Jin, F., Fairley, C. K., Moore, R., Roth, N., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30132-2 · Cited by 524 · see citing works
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina, J.-M., Charreau, I., Spire, B., Cotte, L., Chas, J., Capitant, C., Tremblay, C., Rojas-Castro, D., Cua, E., Pasquet, A., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30089-9 · Cited by 472 · see citing works
Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.
Molina, J.-M., Charreau, I., Chidiac, C., Pialoux, G., Cua, E., Delaugerre, C., Capitant, C., Rojas-Castro, D., Fonsart, J., Bercot, B., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30725-9 · Cited by 449 · see citing works
Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis.
Traeger, M. W., Schroeder, S. E., Wright, E. J., Hellard, M. E., Cornelisse, V. J., Doyle, J. S., & Stoové, M. A. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy182 · Cited by 447 · see citing works
Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review
Mayer, K. H., Agwu, A. L., & Malebranche, D. J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01295-0 · Cited by 430 · see citing works
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER) primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Mayer, K. H., Molina, J.-M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., DeJesus, E., Jessen, H., Grant, R. M., Ruane, P. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31065-5 · Cited by 428 · see citing works
Self-citation
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women
Klatt, N. R., Cheu, R., Birse, K., Zevin, A. S., Perner, M., Noël-Romas, L., Grobler, A., Westmacott, G., Xie, I. Y., Butler, J., et al. (2017) · Science · doi:10.1126/science.aai9383 · Cited by 428 · see citing works
Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection
Traeger, M. W., Cornelisse, V. J., Asselin, J., Price, B., Roth, N. J., Willcox, J., Tee, B. K., Fairley, C. K., Chang, C. C., Armishaw, J., et al. (2019) · JAMA · doi:10.1001/jama.2019.2947 · Cited by 412 · see citing works
The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States
Siegler, A. J., Mouhanna, F., Mera, R. M., Weiss, K. M., Pembleton, E. S., Guest, J. L., Jones, J. S., Castel, A. D., Yeung, H., Kramer, M. R., et al. (2018) · Annals of Epidemiology · doi:10.1016/j.annepidem.2018.06.005 · Cited by 404 · see citing works
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Baeten, J. M., Palanee‐Phillips, T., Brown, E. R., Schwartz, K. D., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Kiweewa, F. M., Nair, G., Mhlanga, F., et al. (2016) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000489577.60775.40 · Cited by 373 · see citing works
Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study
Grulich, A. E., Guy, R., Amin, J., Jin, F., Selvey, C., Holden, J., Schmidt, H.-M. A., Zablotska, I., Price, K., Whittaker, B., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30215-7 · Cited by 366 · see citing works
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Doubeni, C. A., Epling, J. W., et al. (2019) · JAMA · doi:10.1001/jama.2019.6390 · Cited by 312 · see citing works
PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists
Petroll, A. E., Walsh, J. L., Owczarzak, J., McAuliffe, T. L., Bogart, L. M., & Kelly, J. A. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1625-1 · Cited by 309 · see citing works
HIV
Ghosn, J., Taiwo, B., Seedat, S., Autran, B., & Katlama, C. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31311-4 · Cited by 306 · see citing works
Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation
Marcus, J. L., Hurley, L. B., Hare, C. B., Nguyen, D. P., Phengrasamy, T., Silverberg, M. J., Stoltey, J. E., & Volk, J. E. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001129 · Cited by 286 · see citing works
Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations
Murchú, É. Ó., Marshall, L., Hayes, C., Harrington, P., Moran, P., Teljeur, C., & Ryan, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2020-048478 · Cited by 279 · see citing works
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM
Hosek, S., Rudy, B. J., Landovitz, R. J., Kapogiannis, B. G., Siberry, G. K., Rutledge, B. N., Liu, N., Brothers, J., Mulligan, K. M., Zimet, G. D., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001179 · Cited by 267 · see citing works
Self-citation
Preexposure Prophylaxis for the Prevention of HIV Infection
Chou, R., Evans, C., Hoverman, A. S., Sun, C. J., Dana, T., Bougatsos, C., Grusing, S., & Korthuis, P. T. (2019) · JAMA · doi:10.1001/jama.2019.2591 · Cited by 266 · see citing works
HIV pre‐exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery
Celum, C., Delany‐Moretlwe, S., Baeten, J. M., van der Straten, A., Hosek, S., Bukusi, E. A., McConnell, M. A., Barnabas, R. V., & Bekker, L. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25298 · Cited by 259 · see citing works
HIV Preexposure Prophylaxis
Riddell, J., Amico, K. R., & Mayer, K. H. (2018) · JAMA · doi:10.1001/jama.2018.1917 · Cited by 255 · see citing works
Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review
Pleuhs, B., Quinn, K. G., Walsh, J. L., Petroll, A. E., & John, S. A. (2020) · AIDS Patient Care and STDs · doi:10.1089/apc.2019.0189 · Cited by 256 · see citing works
A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?
Sidebottom, D. B., Ekström, A. M., & Strömdahl, S. K. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3463-4 · Cited by 242 · see citing works
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis
Zhang, J., Li, C., Xu, J., Hu, Z., Rutstein, S. E., Tucker, J. D., Ong, J. J., Jiang, Y., Geng, W., Wright, S. T., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00030-3 · Cited by 228 · see citing works
Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men
Eaton, L. A., Kalichman, S. C., Price, D. M., Finneran, S. D., Allen, A. M., & Maksut, J. L. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1690-0 · Cited by 227 · see citing works
Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study.
Jenness, S. M., Weiss, K. M., Goodreau, S. M., Gift, T., Chesson, H., Hoover, K. W., Smith, D. K., Liu, A. Y., Sullivan, P. S., & Rosenberg, E. S. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix439 · Cited by 224 · see citing works
The global response to HIV in men who have sex with men
Beyrer, C., Baral, S., Collins, C., Richardson, E. T., Sullivan, P. S., Sánchez, J., Trapence, G., Katabira, E., Kazatchkine, M. D., Ryan, O., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30781-4 · Cited by 223 · see citing works
Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis
Tan, D. H. S., Hull, M., Yoong, D., Tremblay, C. L., O’Byrne, P., Thomas, R., Kille, J., Baril, J.-G., Cox, J., Giguère, P., et al. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170494 · Cited by 214 · see citing works
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States
Hosek, S., Landovitz, R. J., Kapogiannis, B. G., Siberry, G. K., Rudy, B. J., Rutledge, B. N., Liu, N., Harris, D. R., Mulligan, K. M., Zimet, G. D., et al. (2017) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2017.2007 · Cited by 222 · see citing works
Self-citation
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
Markowitz, M. H., Frank, I., Grant, R. M., Mayer, K. H., Elion, R., Goldstein, D. A., Fisher, C., Sobieszczyk, M. E., Gallant, J. E., Tieu, H., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30068-1 · Cited by 216 · see citing works
The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study
Velloza, J., Khoza, N., Scorgie, F., Chitukuta, M., Mutero, P., Mutiti, K. S., Mangxilana, N. T., Nobula, L., Bulterys, M. A., Atujuna, M., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25463 · Cited by 217 · see citing works
Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics
Sewell, J., Miltz, A. R., Lampe, F. C., Cambiano, V., Speakman, A., Phillips, A. N., Stuart, D., Gilson, R. J. C., Asboe, D., Nwokolo, N. C., et al. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.01.001 · Cited by 214 · see citing works
Self-citation
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
Baeten, J. M., Heffron, R. A., Kidoguchi, L., Mugo, N., Katabira, E. T., Bukusi, E. A., Asiimwe, S. B., Haberer, J. E., Morton, J. F., Ngure, K., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002099 · Cited by 213 · see citing works
Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017
Sullivan, P. S., Mera, R. M., Mouhanna, F., Pembleton, E. S., Guest, J. L., Jones, J. S., Castel, A. D., Yeung, H., Kramer, M. R., McCallister, S. H., et al. (2018) · Annals of Epidemiology · doi:10.1016/j.annepidem.2018.06.009 · Cited by 211 · see citing works
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study
Grinsztejn, B. G. J., Hoagland, B., Moreira, R. I., Kallas, E. G., Madruga, J. V., Goulart, S. P., Leite, I. C., de Freitas, L. A., Martins, L. M. R., Torres, T. S., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30008-0 · Cited by 218 · see citing works
Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men
Kojima, N., Davey, D. J., & Klausner, J. D. (2016) · AIDS · doi:10.1097/qad.0000000000001185 · Cited by 195 · see citing works
Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States
Jenness, S. M., Goodreau, S. M., Rosenberg, E. S., Beylerian, E. N., Hoover, K. W., Smith, D. K., & Sullivan, P. S. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw223 · Cited by 195 · see citing works
Increasing awareness of HIV pre‐exposure prophylaxis (PrEP) and willingness to use HIV PrEP among men who have sex with men: a systematic review and meta‐analysis of global data
Sun, Z., Gu, Q., Dai, Y., Zou, H., Agins, B., Chen, Q., Li, P., Shen, J., Yang, Y., & Jiang, H. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25883 · Cited by 189 · see citing works
A Global Estimate of the Acceptability of Pre-exposure Prophylaxis for HIV Among Men Who have Sex with Men: A Systematic Review and Meta-analysis
Peng, P., Su, S., Fairley, C. K., Chu, M., Jiang, S., Zhuang, X., & Zhang, L. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1675-z · Cited by 186 · see citing works
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
Landovitz, R. J., Li, S., Eron, J. J., Grinsztejn, B. G. J., Dawood, H., Liu, A., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L. M., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30106-5 · Cited by 184 · see citing works
Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013–17
Holt, M., Lea, T., Mao, L., Kolstee, J., Zablotska, I., Duck, T., Allan, B., West, M., Lee, E., Hull, P., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30072-9 · Cited by 182 · see citing works
STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany
MSM Screening Study group, Jansen, K., Steffen, G., Potthoff, A. V., Schuppe, A.-K., Beer, D. T., Jessen, H. K., Scholten, S., Spornraft‐Ragaller, P., Bremer, V., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-4831-4 · Cited by 182 · see citing works
Awareness and willingness to use HIV pre‐exposure prophylaxis among men who have sex with men in low‐ and middle‐income countries: a systematic review and meta‐analysis
Yi, S., Tuot, S., Mwai, G. W., Ngin, C., Chhim, K., Pal, K., Igbinedion, E., Holland, P., Choub, S. C., & Mburu, G. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21580 · Cited by 173 · see citing works
Global Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review and Meta-analysis
Ong, J. J., Baggaley, R. C., Wi, T. E., Tucker, J. D., Fu, H., Smith, M. K., Rafael, S., Anglade, V., Falconer, J., Ofori-Asenso, R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17134 · Cited by 173 · see citing works
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Landovitz, R. J., Li, S., Grinsztejn, B. G. J., Dawood, H., Liu, A., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L. M., Chau, G., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002690 · Cited by 173 · see citing works
Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study
Hoornenborg, E., Coyer, L., Achterbergh, R., Matser, A. A., van der Loeff, M. F. S., Boyd, A. C., van Duijnhoven, Y. T. H. P., Bruisten, S. M., Oostvogel, P. M., Davidovich, U., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30136-5 · Cited by 168 · see citing works
Control and prevention of infectious diseases from a One Health perspective
Ellwanger, J. H., da Veiga, A. B. G., Kaminski, V. D. L., Valverde-Villegas, J. M., de Freitas, A. W. Q., & Chies, J. A. B. (2021) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2020-0256 · Cited by 183 · see citing works
HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project
Eakle, R., Gomez, G. B., Naicker, N., Bothma, R., Mbogua, J., Escobar, M. A. C., Saayman, E., Moorhouse, M. A., Venter, F., Rees, H., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002444 · Cited by 162 · see citing works
A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians
Blackstock, O. J., Moore, B. A., Berkenblit, G. V., Calabrese, S. K., Cunningham, C. O., Fiellin, D. A., Patel, V. V., Phillips, K. A., Tetrault, J. M., Shah, M. P., et al. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3903-z · Cited by 156 · see citing works
Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV
Nguyen, V., Greenwald, Z. R., Trottier, H., Cadieux, M., Goyette, A., Beauchemin, M., Charest, L., Longpré, D., Lavoie, S., Tossa, H. G., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001718 · Cited by 157 · see citing works
Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting.
Montaño, M. A., Dombrowski, J. C., Dasgupta, S., Golden, M. R., Duerr, A., Manhart, L. E., Barbee, L. A., & Khosropour, C. M. (2019) · AIDS and Behavior · doi:10.1007/s10461-018-2252-9 · Cited by 155 · see citing works
Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy
Cohen, M. S., & Chen, J. S. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25355 · Cited by 177 · see citing works
National trends in HIV pre‐exposure prophylaxis awareness, willingness and use among United States men who have sex with men recruited online, 2013 through 2017
Sullivan, P. S., Sanchez, T., Zlotorzynska, M., Chandler, C. J., Sineath, R. C., Kahle, E., & Tregear, S. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25461 · Cited by 153 · see citing works
Interventions to strengthen the HIV prevention cascade: a systematic review of reviews
Krishnaratne, S., Hensen, B., Cordes, J. L., Enstone, J. E., & Hargreaves, J. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30038-8 · Cited by 152 · see citing works
Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study
Liu, A. Y., Vittinghoff, E., von Felten, P., Amico, K. R., Anderson, P., Lester, R., Andrew, E., Estes, I., Serrano, P. A., Brothers, J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy810 · Cited by 146 · see citing works
Redefining Prevention and Care: A Status-Neutral Approach to HIV
Myers, J. E., Braunstein, S., Xia, Q., Scanlin, K., Edelstein, Z. R., Harriman, G., Tsoi, B. W., Andaluz, A., Yu, E., & Daskalakis, D. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy097 · Cited by 144 · see citing works
Usability and Acceptability of a Mobile Comprehensive HIV Prevention App for Men Who Have Sex With Men: A Pilot Study
Sullivan, P. S., Driggers, R. A., Stekler, J. D., Siegler, A. J., Goldenberg, T., McDougal, S. J., Caucutt, J., Jones, J. S., & Stephenson, R. B. (2017) · JMIR mhealth and uhealth · doi:10.2196/mhealth.7199 · Cited by 145 · see citing works
Barriers and Facilitators of PrEP Adherence for Young Men and Transgender Women of Color
Wood, S. M., Gross, R., Shea, J. A., Bauermeister, J. A., Franklin, J., Petsis, D. T., Swyryn, M., Lalley-Chareczko, L., Koenig, H. C., & Dowshen, N. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02502-y · Cited by 145 · see citing works
Geographic Access to Preexposure Prophylaxis Clinics Among Men Who Have Sex With Men in the United States
Siegler, A. J., Bratcher, A. M., & Weiss, K. M. (2019) · American Journal of Public Health · doi:10.2105/ajph.2019.305172 · Cited by 145 · see citing works
Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women
McKinnon, L. R., Liebenberg, L. J. P., Yende‐Zuma, N., Archary, D., Ngcapu, S., Sivro, A., Nagelkerke, N. J. D., Garcia-Lerma, J. G., Kashuba, A. D. M., Masson, L., et al. (2018) · Nature Medicine · doi:10.1038/nm.4506 · Cited by 146 · see citing works
Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics
Pakianathan, M., William, W., Lee, M. J., Avery, J., Green, S., Nathan, B., & Hegazi, A. (2018) · HIV Medicine · doi:10.1111/hiv.12629 · Cited by 142 · see citing works
Reflections on 40 Years of AIDS
Cock, K. M. D., Jaffe, H. W., & Curran, J. W. (2021) · Emerging infectious diseases · doi:10.3201/eid2706.210284 · Cited by 146 · see citing works
High pre‐exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project
Hoagland, B., Moreira, R. I., Boni, R. B. D., Kallas, E. G., Madruga, J. V., Vasconcelos, R. D. P., Goulart, S. P., Torres, T. S., Marins, L. M. S., Anderson, P. L., et al. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21472 · Cited by 141 · see citing works
Gender-based violence and engagement in biomedical HIV prevention, care and treatment: a scoping review
Leddy, A. M., Weiss, E., Yam, E., & Pulerwitz, J. (2019) · BMC Public Health · doi:10.1186/s12889-019-7192-4 · Cited by 140 · see citing works
Pre-exposure Prophylaxis Uptake and Discontinuation Among Young Black Men Who Have Sex With Men in Atlanta, Georgia: A Prospective Cohort Study
Serota, D. P., Rosenberg, E. S., Sullivan, P. S., Thorne, A. L., Rolle, C.-P., del Rı́o, C., Cutro, S. R., Luisi, N., Siegler, A. J., Sanchez, T., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz894 · Cited by 135 · see citing works
MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection.
Hoornenborg, E., Achterbergh, R. C. A., Schim van der Loeff, M. F., Davidovich, U., Hogewoning, A., de Vries, H. J. C., Schinkel, J., Prins, M., & van de Laar, T. J. W. (2017) · AIDS · doi:10.1097/qad.0000000000001522 · Cited by 137 · see citing works
Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study
Storholm, E. D., Volk, J. E., Marcus, J. L., Silverberg, M. J., & Satre, D. D. (2017) · Prevention Science · doi:10.1007/s11121-017-0799-8 · Cited by 137 · see citing works
Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand
Phanuphak, N., Sungsing, T., Jantarapakde, J., Pengnonyang, S., Trachunthong, D., Mingkwanrungruang, P., Sirisakyot, W., Phiayura, P., Seekaew, P., Panpet, P., et al. (2018) · Sexual Health · doi:10.1071/sh18065 · Cited by 137 · see citing works
Environmental fate and ecotoxicological effects of antiretrovirals: A current global status and future perspectives
Ncube, S., Madikizela, L. M., Chimuka, L., & Nindi, M. M. (2018) · Water Research · doi:10.1016/j.watres.2018.08.017 · Cited by 135 · see citing works
HIV epidemiology, prevention, treatment, and implementation strategies for public health
Mody, A., Sohn, A. H., Iwuji, C. C., Tan, R. K. J., Venter, F., & Geng, E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01381-8 · Cited by 138 · see citing works
Acceptability and use of a dapivirine vaginal ring in a phase III trial
Montgomery, E., van der Straten, A., Chitukuta, M., Reddy, K., Woeber, K., Atujuna, M., Bekker, L., Etima, J., Nakyanzi, T., Mayo, A., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001452 · Cited by 134 · see citing works
Exploring Patterns of Awareness and Use of HIV Pre-Exposure Prophylaxis Among Young Men Who Have Sex with Men
Strauss, B. B., Greene, G. J., Phillips, G., Bhatia, R., Madkins, K., Parsons, J. T., & Mustanski, B. S. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1480-0 · Cited by 131 · see citing works
Recent advances in pre-exposure prophylaxis for HIV
Desai, M., Field, N. M., Grant, R. M., & McCormack, S. (2017) · BMJ · doi:10.1136/bmj.j5011 · Cited by 130 · see citing works
Self-citation
Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men
Greene, G. J., Swann, G., Fought, A. J., Carballo‐Diéguez, A., Hope, T. J., Kiser, P. F., Mustanski, B. S., & D’Aquila, R. T. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1565-9 · Cited by 125 · see citing works
Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM
Rolle, C.-P., Rosenberg, E. S., Siegler, A. J., Sanchez, T., Luisi, N., Weiss, K. M., Cutro, S. R., del Rı́o, C., Sullivan, P. S., & Kelley, C. F. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001497 · Cited by 128 · see citing works
Persistence on HIV preexposure prophylaxis medication over a 2‐year period among a national sample of 7148 PrEP users, United States, 2015 to 2017
Coy, K. C., Hazen, R. J., Kirkham, H. S., Delpino, A., & Siegler, A. J. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25252 · Cited by 126 · see citing works
Applying the Information–Motivation–Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men
Walsh, J. L. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2371-3 · Cited by 122 · see citing works
Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming
Hillis, A., Germain, J., Hope, V. D., McVeigh, J., & Hout, M. C. V. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-02855-9 · Cited by 127 · see citing works
Brief Report: The Right People, Right Places, and Right Practices: Disparities in PrEP Access Among African American Men, Women, and MSM in the Deep South
Elopre, L. E., Kudroff, K., Westfall, A. O., Overton, E. T., & Mugavero, M. J. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001165 · Cited by 121 · see citing works
Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation
Cambiano, V., Miners, A. H., Dunn, D. T., McCormack, S., Ong, K. J., Gill, O. N., Nardone, A., Desai, M., Field, N. M., Hart, G., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30540-6 · Cited by 116 · see citing works
Self-citation
Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection – A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis
Werner, R. N., Gaskins, M. D., Nast, A., & Dressler, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208107 · Cited by 118 · see citing works
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
Stephenson, K. E., Wagh, K., Korber, B., & Barouch, D. H. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-080219-023629 · Cited by 115 · see citing works
Sources of HIV infection among men having sex with men and implications for prevention
Ratmann, O., van Sighem, A., Bezemer, D., Gavryushkina, A. “., Jurriaans, S., Wensing, A. M. J., de Wolf, F., Reiss, P., Fraser, C., & cohort, A. O. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad1863 · Cited by 116 · see citing works
Geographic and Individual Associations with PrEP Stigma: Results from the RADAR Cohort of Diverse Young Men Who have Sex with Men and Transgender Women
Mustanski, B. S., Ryan, D. T., Hayford, C. S., Phillips, G., Newcomb, M. E., & Smith, J. D. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2159-5 · Cited by 115 · see citing works
Daily and event‐driven pre‐exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence
Vuylsteke, B., Reyniers, T., Baetselier, I. D., Nöstlinger, C., Crucitti, T., Buyze, J., Kenyon, C. R., Wouters, K., & Laga, M. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25407 · Cited by 112 · see citing works
Long-Acting HIV Drugs for Treatment and Prevention
Gulick, R. M., & Flexner, C. W. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041217-013717 · Cited by 118 · see citing works
Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care
Krakower, D., Maloney, K. M., Powell, V. E., Levine, K., Grasso, C., Melbourne, K., Marcus, J. L., & Mayer, K. H. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25250 · Cited by 111 · see citing works
The preexposure prophylaxis revolution; from clinical trials to programmatic implementation
Mugo, N., Ngure, K., Kiragu, M., Irungu, E., & Kilonzo, N. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000224 · Cited by 114 · see citing works
Expert consensus statement on the science of HIV in the context of criminal law
Barré‐Sinoussi, F., Karim, S. S. A., Albert, J., Bekker, L., Beyrer, C., Cahn, P. E., Calmy, A., Grinsztejn, B. G. J., Grulich, A. E., Kamarulzaman, A., et al. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25161 · Cited by 117 · see citing works
The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion
Donnell, D. J., Ramos, E. M., Celum, C., Baeten, J. M., Dragavon, J., Tappero, J. W., Lingappa, J. R., Ronald, A., Fife, K. H., & Coombs, R. W. (2017) · AIDS · doi:10.1097/qad.0000000000001577 · Cited by 110 · see citing works
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial
Bekker, L., Roux, S., Sebastien, E., Yola, N., Amico, K. R., Hughes, J. P., Marzinke, M. A., Hendrix, C. W., Anderson, P. L., Elharrar, V., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30156-x · Cited by 114 · see citing works
Self-citation
Disclosure of Same-Sex Behaviors to Health-care Providers and Uptake of HIV Testing for Men Who Have Sex With Men: A Systematic Review
Qiao, S., Zhou, G., & Li, X. (2018) · American Journal of Men s Health · doi:10.1177/1557988318784149 · Cited by 112 · see citing works
Da evidência à ação: desafios do Sistema Único de Saúde para ofertar a profilaxia pré-exposição sexual (PrEP) ao HIV às pessoas em maior vulnerabilidade
Zucchi, E. M., Grangeiro, A., Ferraz, D., Pinheiro, T. F., Alencar, T., Ferguson, L., Estevam, D. L., & Munhoz, R. (2018) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00206617 · Cited by 125 · see citing works
Pre-Exposure Prophylaxis (PrEP) Use and Condomless Anal Sex: Evidence of Risk Compensation in a Cohort of Young Men Who Have Sex with Men
Newcomb, M. E., Moran, K., Feinstein, B. A., Forscher, E. C., & Mustanski, B. S. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001604 · Cited by 111 · see citing works

HIV moments and pre-exposure prophylaxis
Grant, R. M., & Glidden, D. V. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30125-8 · Cited by 15 · see citing works
PrEP: why are we waiting?
The Lancet, H. I. V. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00185-x · Cited by 5 · see citing works
Preexposure tenofovir–emtricitabine reduced HIV infection in men who have unprotected anal sex with men
Sacks, H. S. (2016) · Annals of Internal Medicine · doi:10.7326/acpjc-2016-164-2-003
Editorial Commentary: Scaling Up Antiretroviral Preexposure Prophylaxis: Moving From Trials to Implementation
Mayer, K. H., & Krakower, D. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ665 · Cited by 19 · see citing works
Antiretroviral chemoprophylaxis: new successes and questions
Mayer, K. H. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60494-9 · Cited by 1 · see citing works

Authors: McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., Mackie, N., Bowman, C., Lacey, C. J., Apea, V., Brady, M., Fox, J., Taylor, S., Antonucci, S., Khoo, S. H., Rooney, J., Nardone, A., Fisher, M., McOwan, A., Phillips, A. N., Johnson, A. M., Gazzard, B., & Gill, O. N.
Affiliations: Chelsea and Westminster Hospital NHS Foundation Trust (GB)
MRC Clinical Trials Unit at UCL (GB)
Public Health England (GB)
Central and North West London NHS Foundation Trust (GB)
Royal Sussex County Hospital (GB)
Homerton University Hospital NHS Foundation Trust (GB)
Imperial College Healthcare NHS Trust (GB)
Sheffield Teaching Hospitals NHS Foundation Trust (GB)
University of York (GB)
Barts Health NHS Trust (GB)
King's College Hospital NHS Foundation Trust (GB)
Guy's and St Thomas' NHS Foundation Trust (GB)
Heart of England NHS Foundation Trust (GB)
University of Liverpool (GB)
Gilead Sciences (United States) (US)
University College London (GB)
Corresponding author: McCormack, Sheena
ORCID: McCormack, Sheena
Dunn, David T
Desai, Monica
Dolling, David I
Gafos, Mitzy
Gilson, Richard
Sullivan, Ann K
Clarke, Amanda
Lacey, Charles J
Apea, Vanessa
Brady, Michael
Fox, Julie
Taylor, Stephen
Khoo, Saye H
Rooney, James
Nardone, Anthony
Fisher, Martin
Phillips, Andrew N
Gill, Owen N
Venue: The Lancet
Publisher: Elsevier BV
Published: 2016-01
Volume: 387
Issue: 10013
Pages: 53-60
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(15)00056-2
PMC: PMC4700047
OpenAlex: W1413161224
Cited by: 1,878
References: 24
Citations by year: 2026: 61 · 2025: 122 · 2024: 136 · 2023: 163 · 2022: 174 · 2021: 201 · 2020: 181 · 2019: 240 · 2018: 207 · 2017: 213 · 2016: 152 · 2015: 23 · 2013: 1
FWCI: 154.11
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: The Lancet (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: National Institute for Health and Care Research (ACF-2008-20-002, NF-SI-0508-10244)
Public Health England
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords: tenofovir disoproxil fumarate, emtricitabine, risk compensation, men who have sex with men, post-exposure prophylaxis, trial retention, PrEP adherence, sexual health clinics
MeSH terms: Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Adult, Bisexuality, England, Humans, Male, Pilot Projects, HIV-1, HIV Infections, Treatment Outcome, Condoms, Homosexuality, Male, Anti-HIV Agents, Unsafe Sex, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks